… The development of targeted therapies that inhibit ALK has revolutionized … targeting other
fusions in solid tumours. Crizotinib, a type I kinase inhibitor, was the first ALK-targeted therapy …

… resistance mechanisms in the context of chemotherapy and targeted therapy … targeting
myeloid cell subsets is of paramount importance to increase the effectiveness of cancer therapy. …

… In contrast, molecularly targeted therapies have been rationally designed to interact with …
a unique therapeutic target for the RTK inhibitor imatinib mesylate. Targeting solid tumours is a …

… Patients with solid tumours harbouring high-level MET amplifications have a greater likelihood
of benefit from single-agent or combination MET-targeted therapies than those with lower …

… , such as tyrosine kinase inhibitors (TKI) or mammalian target of rapamycin (mTOR) … DDIs
that involve targeted therapies approved by the FDA for the treatment of solid tumours for more …

The majority of human epithelial cancers is frequently characterized by a functional activation
of the epidermal growth factor receptor (EGFR)-driven- pathways. Today, two classes of …

… This review paper focuses on cardiotoxicity of targeted drugs used in the treatment for
solid tumours. Recent findings from research studies have elucidated some of the …

… Among these eight solid tumor types we discussed, it seems … affected especially before
targeted therapy application. Then … and clinical trials in these eight solid cancer types (as shown …

… Recent developments in synthetic medicinal chemistry and design of antibody therapeutics
have made important contributions to the development of targeted therapies. Currently, …

… Oncogene addiction becomes the rationale for targeted therapy of solid tumours enabling a
… by avoiding expensive but ineffective therapies. Targeted therapies for advanced lung cancer…